Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $10.50 Consensus Target Price from Analysts
02:16am, Wednesday, 14'th Jan 2026
Adverum Biotechnologies, Inc. (NASDAQ: ADVM - Get Free Report) has been given a consensus recommendation of "Hold" by the six analysts that are presently covering the company, Marketbeat Ratings repor
First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
07:37am, Wednesday, 10'th Dec 2025
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
08:28am, Tuesday, 09'th Dec 2025
INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Ac
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
07:00am, Monday, 01'st Dec 2025
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And Do
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
06:18pm, Wednesday, 19'th Nov 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday
02:00am, Saturday, 01'st Nov 2025
Adverum Biotechnologies (NASDAQ: ADVM - Get Free Report) is expected to be issuing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders
09:40am, Monday, 27'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is fair to Adverum
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
05:30pm, Friday, 24'th Oct 2025
NEW YORK , Oct. 24, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
MILWAUKEE , Oct. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Adverum (Nasdaq: ADVM) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.
Eli Lilly to buy gene therapy developer Adverum in about $262 million deal
10:11am, Friday, 24'th Oct 2025
Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 million, aiming to strengthen its pipeline with an experimental eye disease tr
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. is Fair to Shareholders
09:39am, Friday, 24'th Oct 2025
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) to Eli Lilly and Company is
Lilly to Acquire Adverum Biotechnologies
08:30am, Friday, 24'th Oct 2025
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly
Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026) ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 (
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 05'th Sep 2025
REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement
